Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07265028 in Advanced or Metastatic Solid Tumors
NCT05233436Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pf-07265028 in solid tumor (advanced stage), gastric cancer (GC), gastroesophageal junction cancer and 3 more, sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities at 4 weeks, Adverse events at 2 years and 2 more. Started Feb 2022; status: terminated.
02
Drugs
pf-07265028
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction cancerurothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05233436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233436.